LGI1 and neoplasm: No significant differences were found in sex, frequency of tumor association, prognosis and type of immunotherapy between anti-NMDAR positive AE patients and patients positive for other AE-related antibodies (anti-LGI1, anti-GABABR, anti-Caspr2).